Preliminary results of clinical use of colchicine in COVID-19 treatment

Abstract

We report a case of the use of colchicine in a patient infected with SARS-CoV-2 virus. A 37-year-old man with COVID-19 presented with moderate symptoms, mild pulmonary impairment and elevated inflammatory markers, suggesting an increased risk of cytokine storm and possible worsening of clinical condition. Experimental use of colchicine resulted in an 85% decrease in C reactive protein levels 3 days after treatment initiation and a 182.6% decrease in interleukin-6 levels 8 days after treatment initiation. Due to the lack of effective therapies, it is important to search for potential compounds and compounds that focus on controlling the danger caused by systemic inflammation in COVID-19. Although further research is needed in the area of colchicine and viral infection, preliminary efficacy was observed.

An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy

“…We provide some examples. (A) In targeting TNT, the proven clinical efficacy of Colchicine, a weel-known microtubule inhibitor that might interfere with TNT formation 63 , 64 , can be suggestive evidence of the role of TNT in COVID19 pathogenesis. (B) Several drugs that suppress cell fusion have been tested in vitro 47 ; among them, Niclosamide was effective in cell protection against virus-induced cell death 45 , 47 .…”

An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy

“…However, we report that some suitable drugs have been tested already. In targeting TNT, the proven clinical e cacy in treating COVID19 of Colchicine, a microtubule inhibitor that might interfere with TNT formation 60,61 , can be suggestive evidence of the role of TNT in COVID19 pathogenesis. Drugs that suppress cell fusion have been tested in vitro 44 ; among them, niclosamide, an oral anti-helminthic agent, was effective in cell protection against virus-induced cell death 42,44 .…”